Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 14, 2023

SELL
$0.65 - $1.56 $1.07 Million - $2.57 Million
-1,646,000 Reduced 68.7%
750,000 $495,000
Q2 2023

Aug 14, 2023

BUY
$1.4 - $5.06 $3.35 Million - $12.1 Million
2,396,000 New
2,396,000 $3.64 Million

Others Institutions Holding ELEV

About Elevation Oncology, Inc.


  • Ticker ELEV
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 23,300,900
  • Market Cap $12.3M
  • Description
  • Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced sol...
More about ELEV
Track This Portfolio

Track Armistice Capital, LLC Portfolio

Follow Armistice Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Armistice Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Armistice Capital, LLC with notifications on news.